China bio firm CanSinoBIO mulls issuing GDR on Swiss Exchange

China's CanSino Biologics Inc (CanSinoBIO) intends to issue global depository receipts (GDR) and to list on the SIX Swiss Exchange, the company said on Tuesday in an announcement filed to the Hong Kong Stock Exchange (HKEX).

CanSinoBIO is the first Chinese company to issue GDR on the SIX Swiss Exchange in 2023.

With this move, the firm aims to further broaden international financing channels, enhance international brand and image, meet overseas business development needs, and promote its globalization strategy.

Founded in China in 2009, CanSinoBIO is an industry-leading biopharmaceutical company dedicated to research and development, manufacturing and commercialization of innovative vaccine products that meet PRC and international standards.